Keylicon Biosciences provides a next‑generation self‑amplifying RNA (saRNA) platform that replicates inside host cells to generate higher antigen levels from lower initial doses.
Funding
Funding not disclosed
Founders
Product
Problem
Current mRNA vaccine and therapeutic platforms often require high doses and multiple administrations to achieve sufficient antigen expression and durable immune responses, limiting scalability and increasing production costs.
Solution
Keylicon employs a next‑generation self‑amplifying RNA (saRNA) platform that replicates within host cells to produce higher levels of antigen from a smaller initial dose. The amplified expression extends the duration of immune stimulation, enabling more durable protection with fewer injections. By leveraging the inherent replication of saRNA, the platform reduces manufacturing volume and cost while maintaining high efficacy. This approach is applicable to both prophylactic vaccines against infectious diseases and therapeutic RNA treatments for other medical indications.
Target Audience
Primary customers are pharmaceutical and biotech companies developing vaccines and RNA‑based therapeutics, as well as research institutions seeking a high‑efficacy platform for preclinical and clinical programs.
Features
- Self‑amplifying RNA construct that autonomously replicates in vivo to boost antigen production
- Lower required dose compared with conventional mRNA, improving manufacturing efficiency
- Extended antigen expression leading to longer-lasting immune responses
- Modular design allowing rapid adaptation to new targets across infectious and therapeutic areas
- Compatibility with existing lipid nanoparticle delivery systems for scalable formulation